GCH Technology Co., Ltd. Overview
Data conflict on business description. Two aggregator profiles (financialfilings.com and disfold.com) describe the company as a power-semiconductor or semiconductor-materials maker. That description is incorrect. Every primary filing shows a specialty polymer-additives company that is now expanding into electronic resins for copper-clad laminates (CCL).
GCH Technology is China's leading domestic producer of polymer nucleating agents. These are additives that raise the crystallinity, clarity, stiffness or toughness of polypropylene and polyethylene. The company is also a leading Chinese supplier of synthetic hydrotalcite, used as a lead-free PVC heat stabiliser and as an acid scavenger in polyolefin production. Its core franchise sits upstream of high-performance resin production at Sinopec, PetroChina, CNOOC-Shell, Wanhua, Hengli and other petrochemical majors. That franchise earns gross margins above 55% on nucleating agents, far above Chinese additive peers. The investment case rests on import substitution against Milliken, Adeka and Kyowa Chemical. Overseas sales are accelerating (+52.6% in FY2025), helped by the acquisition of France-based Palmarole Trading. Since January 2026 the company has been repositioning toward electronic-grade PPO resin and halogen-free flame retardants for high-frequency/high-speed CCL used in AI servers and communications. Equity markets have re-rated the shares more than twofold on this story, ahead of any material revenue contribution.
Company's own description (FY2023 and FY2025 annual reports, paraphrased)
The company describes itself as a high-tech manufacturer of environmentally friendly, safe, high-performance specialty polymer additives. Its products sit at the upstream core of high-performance resin and modified-plastics manufacturing. They improve the optical and mechanical properties and stability of commodity resins. The resulting resins serve food-contact packaging, medical devices, pharmaceutical packaging, infant products, automotive parts, appliances, building materials and agricultural facilities.
The company holds several state designations:
-
MIIT national "Specialised, Refined, Distinctive and Innovative" (专精特新) "little giant"
-
National Manufacturing Single-Item Champion, for nucleating agents
-
National Green Factory
It also says it was the first Chinese company to obtain US FDA food-contact-substance clearance for its products. It holds Novolen (2017) and Unipol (2019) polypropylene process-licensor qualifications, which put it on major petrochemical approved-vendor lists.
Product families (self-produced)
-
Nucleating agents (成核剂): clarifying (transparent), stiffening, and β-crystal toughening grades, sold as single additives and as nucleator-containing compound blends.
-
Synthetic hydrotalcite (合成水滑石): general-purpose, high-transparency ternary (Mg-Al-Zn) and flame-retardant grades, used as PVC heat stabiliser and polyolefin halogen/acid scavenger.
-
Antioxidants (抗氧剂): specialty hindered-phenol grades, added via the 2023 acquisition of Keao Chemical (科澳化学).
-
Compound additives (复合助剂): dust-free one-pack blends. These include "NDO" compounds, which contain none of GCH's own nucleators or hydrotalcite.
-
Electronic materials (since Jan 2026): electronic-grade PPO (polyphenylene ether) resin and high-frequency/high-speed flame retardants for CCL. These came via the 80.89% acquisition of Guangdong Juxun New Materials (聚讯新材料).
Trading business
The company also runs a trading business, split into two models:
Proprietary trading (自主贸易): booked gross, with inventory and credit risk carried by the company.
Agency trading (代理贸易): booked net, with no title to goods.
Traded products include general-purpose antioxidants, polypropylene, catalysts, slip/anti-block agents and other additives. Five group entities carry this out: the parent, Shanghai Chenghe International Trade, Guangzhou Chenghe Plastics New Materials, Hong Kong Chenghe Technology and Tianjin Xindafeng Import & Export (Inquiry Reply).
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | Essentially 100% product sales. FY2025: self-produced additives CNY 895.8M (91.7%) and trading CNY 81.4M (8.3%). No subscription or licensing revenue. A small amount of technical-service revenue is disclosed for one customer (Inquiry Reply). |
| Sales model | Direct sales to two customer types. End customers (petrochemical majors, resin compounders, additive blenders) took CNY 651.3M in FY2025. Traders on a buy-out basis took CNY 244.5M. Consignment ("zero-inventory") arrangements apply for some petrochemical customers. |
| Production model | Make-to-order with about one month of safety stock. Production lines and core equipment are designed in-house. |
| Procurement | Aromatic aldehydes, aromatic carboxylic acids, antioxidants and other intermediates, bought "per production plan". |
| Value-chain position | Upstream specialty-additive supplier to polyolefin and PVC producers, and to compounders for packaging, automotive, appliance and medical end-uses. New electronic-materials step: resin and flame-retardant supplier to CCL makers, which supply PCB makers serving AI servers and telecoms. |
| Customer concentration | Top-5 customers were 31.86% of revenue in FY2024 and 35.68% in FY2025. The largest customer, a petrochemical major (name withheld), accounted for 13.42% in FY2025 (Inquiry Reply). |
Independent characterisation
GCH is best understood as a niche "molecule-plus-formulation" specialty chemicals company. Its moat is built from three things:
-
process know-how in sorbitol/phosphate-type clarifiers and hydrotalcite synthesis;
-
long qualification cycles with state-owned petrochemical majors;
-
a cost advantage over Milliken (US) and Japanese incumbents.
Margins are structurally high, about 45% gross and about 29% operating. Absolute scale remains small, below CNY 1bn of revenue. Capacity utilisation after the FY2024 Nansha expansion was only 55–57% in FY2025.
The 2026 pivot into CCL resins changes the risk profile. GCH moves from a slow-compounding import-substitution story into a capital-intensive, qualification-driven electronic-materials race. It does so against Shengquan, Dongcai, SABIC, Mitsubishi Gas Chemical and Asahi Kasei. The balance sheet carries a large "treasury" layer:
-
CNY 1.15bn of deposits, certificates and principal-protected notes at end-2025;
-
CNY 854M of short-term "debt", mostly discounted bank-acceptance bills not derecognised.
The fundamental net cash position is therefore stronger than headline gearing suggests, but it is opaque. The SSE explicitly queried it.
End-markets served
| End-market | Additive role | Primary product |
|---|---|---|
| Food and beverage packaging (thin-wall injection, clear cups, microwaveable containers) | Clarity, heat resistance, cycle time | Clarifying and stiffening nucleators |
| Medical devices and pharmaceutical packaging (syringes, IV sets, blood bags) | Clarity, safety, lead-free | Nucleators, high-transparency hydrotalcite |
| Automotive (bumpers, door panels, thin-wall modified PP) | Stiffness and toughness balance | Stiffening and β-nucleators |
| Household appliances | Stiffness, "plastic-for-steel" substitution | Nucleators, compounds |
| PVC pipes, profiles, cables, artificial leather | Lead-free heat stabilisation | Synthetic hydrotalcite |
| Polyolefin polymerisation (petrochemical plants) | Halogen/catalyst-residue scavenging | Hydrotalcite, NDO compounds |
| Agricultural film | IR absorption, heat retention | Modified hydrotalcite |
| Nylon, rubber, fibres, wire and cable | Anti-ageing | Specialty antioxidants |
| Battery separators (polyolefin microporous film) | Pore structure | Nucleators |
| CCL / PCB for AI servers and telecoms (new) | Low-Dk/Df resin, halogen-free flame retardancy | Electronic-grade PPO, HF/HS flame retardants |
Strategy
Stated strategy themes (FY2023–FY2025 ARs; investor communications; paraphrased)
-
Import substitution in core additives. Expand domestic share of nucleators, where the import-substitution rate rose from 19% in 2017 to 28% in 2022, about 30% in 2023, and a projected 34% in 2025. Do the same in high-end hydrotalcite, where Kyowa Chemical, Sakai Chemical and Clariant still dominate.
-
Internationalisation. Use cost-performance parity with Milliken to win global petrochemical accounts. The Palmarole acquisition is the channel platform for Europe and the Middle East.
-
Platform upgrade into electronic materials. Move from "traditional resin-additive leader" to a "high-frequency/high-speed electronic-materials platform" (Guosen characterisation, consistent with management's Dongguan investment rationale).
-
Green and low-carbon processes. CO2-route hydrotalcite, ISO 50001 certification, national green factory, and "zero-waste factory" status in Baiyun District.
-
"Quality, Efficiency and Returns" action plan (提质增效重回报). An SSE-encouraged programme, with a 2026 plan and a half-year evaluation approved in August 2026.
Strategic initiatives in the last 24 months
| Date | Initiative | Detail / target |
|---|---|---|
| Apr–Jun 2025 | Attempted entry into sputtering targets (Yingri Technology) | Indicative CNY 1.8bn valuation for 100%; at least 51% stake; terminated |
| Dec 2025 | Palmarole Trading SAS acquisition | USD 9M for 100% plus a USD 15M capital increase; overseas regulatory approvals received Dec 2025 and Feb 2026 |
| Dec 2025 | CETC Yizhihang 48% | CNY 6.18M net; low-altitude economy and defence diversification |
| Jan 2026 | Juxun New Materials 80.89% | Entry into electronic PPO and HF/HS flame retardants |
| Mar–May 2026 | 2026 Restricted Stock Incentive Plan | 6.72M shares (post-adjustment) at CNY 21.43 to 62 grantees. |
| Jun 2026 | Dongguan project | Up to CNY 1.3bn; PPO 2,500 t, flame retardant 2,500 t, high-end hydrotalcite 20,000 t; financed by raised funds, own funds and bank loans |
| Jun 2026 | UN Global Compact accession | First Communication on Progress due 31 Jul 2027 |
| Jun–Aug 2026 | Management share purchase | CNY 30–60M range; CNY 59.92M executed |
| 2,026 | R&D build-out | 28 projects in progress at June 2026: 4th-generation organophosphate nucleator, hydrotalcite for coatings, degradable and engineering plastics, electronic materials |
Medium-term targets and guidance
Management has published no numerical medium-term revenue or margin targets. The only quantified forward data are capacity plans (Dongguan) and sell-side estimates (Guosen; Section 22).
The FY2025 capital-allocation choice signals priority for reinvestment over payout. The board chose a 4-for-10 capitalisation issue and no final cash dividend, explicitly citing electronic-materials expansion and R&D funding needs (FY2025 AR summary).
Products & Services
The company reports more than 200 product grades at scale (FY2023 AR). The catalogue below follows the product families in its filings and its English product taxonomy as summarised by S&P: polyolefin clarifiers, high-performance nucleators, β-nucleators, PA nucleators, PVC and polyolefin acid scavengers, Non-Dust One-pack (NDO), preblends, masterbatches, HALS/UVA light stabilisers and anti-block agents.
Nucleating agents (FY2025 revenue CNY 595.8M; GM 55.6%)
| Product line | Function / key specification (company disclosures) | Target application | Status |
|---|---|---|---|
| Transparent nucleators (clarifiers) | Haze reduced by more than 60%; heat-deflection and crystallisation temperature +5–10 °C; flexural modulus +10–15%; shorter cycle time | High-melt-flow PP; clear PP cups, food containers, infant bottles, medical syringes | Mature; capacity reallocated toward clarifiers in 2024 because of higher value-add |
| Stiffening nucleators | Flexural modulus and strength +20% or more; HDT +15–25 °C; warpage control | Thin-wall automotive PP, high-stiffness/high-toughness PP, packaging | Mature. Some stiffening-agent equipment was idle in 2025 because demand fell short of plan (Inquiry Reply). |
| β-crystal toughening nucleators | β-form conversion above 80%; impact strength up more than 3×. Tetrahydrophthalic-anhydride metal salt grade claimed as an industry first and registered as a new chemical substance in China. | Impact PP, pipes, β-PP | Mature; niche |
| Calcium carboxylate stiffening nucleator | Stiffening plus transparency and thermal stability for high-speed thin-wall injection moulding | Thin-wall packaging (delivery and express logistics) | Launched about 2022 as an import substitute |
| PA (nylon) nucleators | Crystallisation control in polyamide | Engineering plastics | Listed in product range; details not disclosed |
| 4th-generation organophosphate nucleator | Benchmarked against Milliken's Millad series | High-end clear PP | Under customer validation as of Sep 2026 investor Q&A; timetable not disclosed |
| Nucleator compound additives | Customised one-pack blends containing GCH nucleators | Petrochemical resin grades | Mature |
Pricing (FY2025, Inquiry Reply). Average selling price was CNY 51,300/t (FY2024: CNY 52,500/t). Average unit cost was CNY 22,800/t (FY2024: CNY 23,200/t).
Synthetic hydrotalcite (FY2025 revenue CNY 126.2M; GM 44.6%)
| Product line | Composition / function | Application | Notes |
|---|---|---|---|
| General-purpose hydrotalcite | Mg-Al. PVC heat stabiliser; polyolefin acid scavenger with 4–6× the acid-absorption capacity of calcium stearate | PVC pipes, profiles, cables; PP/PE polymerisation | Supplied at scale to Adeka and Baerlocher (heat-stabiliser makers). The only domestic hydrotalcite specified by Sinopec besides imports. |
| High-transparency ternary hydrotalcite | Mg-Al-Zn; transparency 30–50% higher than general grades | Transparent PVC, medical PVC, high-end PP film | Replacing Kyowa Chemical and Sakai Chemical imports; extended into coatings in 2025 |
| Flame-retardant hydrotalcite | Halogen-free, low-smoke, non-corrosive; guanidine sulfamate and phytate intercalated grades | Halogen-free flame-retardant cable | One Chinese invention patent granted in 2023 |
| Agricultural-film hydrotalcite | EDTMP-intercalated; IR absorption at 7–25 µm, above 65% absorption at 9–11 µm | Greenhouse film | One Chinese invention patent granted in 2023 |
| CO2-route hydrotalcite (process) | Made from Al(OH)3, Mg(OH)2/MgO and CO2; no by-product salt and no wastewater | All grades | Green-process technology disclosed in FY2022 AR |
Pricing (FY2025). Average selling price CNY 17,700/t (FY2024: CNY 16,600/t). Unit cost CNY 9,800/t (FY2024: CNY 8,800/t).
Antioxidants (FY2025 revenue CNY 114.0M; GM 11.6%)
| Product line | Function | Application | Notes |
|---|---|---|---|
| Specialty hindered-phenol antioxidants | Primary radical-scavenging anti-ageing | Nylon, polyolefins, wire and cable, rubber elastomers, polyether-polyurethane | From the Keao Chemical acquisition (2023). Customers include Sinopec, CNOOC, Adeka and SI Group (FY2023 AR). |
| Custom antioxidant blends | Formulated packages | Same | Purification step added in 2025 for high-end grades |
Pricing (FY2025). Average selling price CNY 23,200/t, up from CNY 16,000/t; unit cost CNY 20,500/t, up from CNY 13,600/t.
Compound additives, including NDO (FY2025 NDO revenue CNY 59.9M; GM 23.6%)
| Product line | Description | Target customer |
|---|---|---|
| NDO (Non-Dust One-pack) | Granular, dust-free, all-in-one additive packages containing no GCH-made nucleator or hydrotalcite | Sinopec, PetroChina, CNOOC-Shell and others |
| Preblends and masterbatches | Additive premixes and resin masterbatches | Compounders |
| HALS and UVA light stabilisers; anti-block and slip agents | Partly traded or blended | Film and packaging producers |
The company reports supplying more than 100 compound formulations to Sinopec, PetroChina, CNOOC-Shell, Yanchang Petroleum, Wanhua Chemical, Hengli Petrochemical, HMC (Thailand) and Formosa. NDO capacity utilisation was only 22.7% in FY2025. Production is deliberately intermittent because NDO is a commoditised, price-competitive line (Inquiry Reply).
Pricing (FY2025). Average selling price CNY 25,700/t, down from CNY 34,900/t because of customer mix.
Electronic materials (new in FY2026)
| Product | Function | Status |
|---|---|---|
| Electronic-grade PPO (polyphenylene ether) resin | Low-dielectric (low Dk/Df) matrix resin for high-frequency/high-speed CCL | In stable supply to CCL customers via Juxun (Guosen, Jun 2026). Planned Dongguan capacity: 2,500 t/yr. |
| High-frequency/high-speed halogen-free flame retardants | Flame retardancy for M6-and-above CCL with high purity and dielectric performance | Supplied to CCL customers. Planned Dongguan capacity: 2,500 t/yr. |
Juxun reported FY2025 revenue of CNY 26.57M and a net loss of CNY 6.15M.
Trading products (FY2025 revenue CNY 81.4M)
| Category | Model | Notes |
|---|---|---|
| General-purpose antioxidants, slip/anti-block agents, compound and premix additives | Proprietary (gross) | Declined in FY2025 on weaker demand |
| Catalysts (new in 2025), polypropylene, polyethylene, styrene-isoprene polymers, PTA | Agency (net) | Main customers are traders serving Middle East and domestic petrochemical plants |
Pricing model (all lines). Negotiated contract pricing, bids and tenders for petrochemical customers, with consignment stock for some majors. List prices are not disclosed.
Financial Narrative
Basis. The tables below use S&P Global Market Intelligence standardised data (StockAnalysis.com, updated 20 Aug 2026), cross-checked against company filings on CFi.cn and annual-report summaries.
Known differences between S&P and company data:
-
FY2023 revenue in S&P is pre-restatement (CNY 799.63M); the company-restated figure is CNY 788.90M.
-
S&P "operating income" excludes interest income and investment income. The PRC-GAAP "operating profit" is higher: CNY 329.3M in FY2025 and CNY 291.7M in FY2024.
-
Per-share data are adjusted for the 1.4× capitalisation issue of June 2026.
Income statement
Notes on non-recurring net income. FY2021 is from the FY2021 AR. FY2024 and FY2025 are from CFi.cn.
EPS as originally reported (pre-adjustment, CNY): FY2021 1.35; FY2025 1.49. Guosen reports pre-bonus EPS of CNY 1.85 for FY2024 and CNY 1.46 for FY2025 on the post-bonus share base.
DPS conventions. S&P assigns dividends to the year in which they are paid or declared. Company-declared cash returns by fiscal year:
-
FY2021: CNY 50.00M (31.84% payout).
-
FY2022: no dividend, deferred because of the 2023 private placement.
-
FY2023: CNY 81.20M interim plus CNY 99.36M final plus CNY 23.82M buyback, totalling CNY 204.38M (90.38% of net profit).
-
FY2025: CNY 42.66M interim only (15.5% payout), plus a 4-for-10 capitalisation issue.
CAGR, FY2021–FY2025: revenue 14.1%; net income 15.1%; EBITDA 15.3%. FY2019–FY2021 revenue grew from CNY 392.1M to CNY 576.2M, a 21.2% CAGR (FY2021 AR).
Commentary.
Deceleration: Revenue growth slowed from 25% in FY2021 to about 9–12% in FY2024–FY2025. Net margin stayed between 27% and 29% throughout.
Gross margin trough and recovery: The FY2022 gross-margin trough of 41.9% reflects raw-material inflation and a heavier trading mix. The FY2025 peak of 45.0% reflects a smaller, more agency-weighted trading business and higher utilisation of the new Nansha capacity.
Treasury income: Pre-tax income runs about 3–5 points of revenue above EBIT because of the treasury book: interest income of CNY 43.3M plus investment income of CNY 17.7M in FY2025. This is large relative to a company of this size.
Earnings quality: Recurring net profit is about 95% of reported profit (FY2025: CNY 263.8M of CNY 275.8M).
Interim results — H1 2026 and quarterly run-rate
Source: 2026 half-year report summary, 21 Aug 2026. H1 2025 figures are restated.
How the quarterly figures are derived:
-
Q3 2025: nine-month CNY 227.79M less H1 CNY 147.25M.
-
Q4 2025: full year less nine months.
-
Q2 2026: H1 less Q1. Q1 2026 from the Q1 report.
-
Q3 2025 revenue uses restated nine-month revenue.
The H1 2026 profit decline has four identified drivers:
-
Selling expense rose 54.7% to CNY 25.6M, reflecting the Palmarole distribution consolidation and overseas expansion.
-
Management expense rose to CNY 39.9M, with 2026 share-incentive amortisation starting in Q2.
-
Foreign-exchange losses (S&P TTM shows CNY −14.8M).
-
Juxun losses.
Non-recurring gains, mainly fair-value gains of CNY 15.6M, provided 17.7% of H1 net profit. Recurring profit fell 22.4%.
Q2 2026 net profit of CNY 38.5M was the weakest quarter since listing. The sharp swing from Q1's CNY 90.2M signals rising cost intensity, as electronic materials and overseas distribution are built out ahead of revenue.
Balance sheet
Interim balance sheet (30 Jun 2026): total assets CNY 3,513.7M; equity attributable CNY 1,643.9M (H1 2026 report). Goodwill rose to CNY 94.3M at 31 Mar 2026 after the Juxun acquisition (S&P).
Commentary — the "bill-financing" balance sheet. The jump in short-term debt from CNY 1.3M (FY2021) to CNY 1.5bn (FY2023) is not conventional borrowing. The SSE inquiry reply explains the mechanism:
-
Intra-group and trading-related bank-acceptance bills are discounted at 0.60–1.65%.
-
Because they carry recourse, they stay on the balance sheet as "short-term borrowings": CNY 853.9M of FY2025's CNY 854.0M.
-
In parallel, the group holds CNY 1.15bn of time deposits, large-denomination certificates and USD principal-protected zero-coupon notes yielding 1.65–6.28%.
-
Of these, CNY 592M is pledged against bill and letter-of-credit issuance.
Interest expense of CNY 17.3M against interest plus investment income of CNY 53.1M (excluding receipt trading) shows the carry is positive. Restricted assets totalled CNY 675.7M at end-2025.
Gross leverage optics therefore overstate risk. They do, however, create rollover dependence on bank credit lines. At 31 Mar 2026, short-term borrowings had risen again to CNY 973.3M.
Cash flow
Notes:
-
The company-restated FY2023 operating cash flow is CNY 163.69M (Inquiry Reply restatement table).
-
Buybacks are derived from the change in treasury stock: CNY −23.82M at FY2023 and CNY −100M at FY2024.
-
H1 2026 operating cash flow was CNY 163.4M.
Commentary. Free cash flow fell to CNY 44M in FY2023 because Nansha capex peaked and receivables and other working capital absorbed cash. It recovered to CNY 218M in FY2025 as capex normalised. Receivables are a growing watch-point:
-
Gross accounts receivable rose 31% in FY2025, against 12% revenue growth.
-
Receivables reached 30.2% of revenue in FY2025 (25.8% in FY2024; 20.0% in FY2023).
-
Post-period collection of FY2025 receivables reached only 86.1% by 31 May 2026, against 98.8% for FY2024 at the equivalent point.
Ratios
Sources and derivations:
-
ROE, ROA, ROIC, liquidity, leverage and turnover ratios are from S&P.
-
Interest coverage is derived as S&P EBIT divided by S&P interest expense.
-
DIO is derived as inventory divided by cost of revenue, times 365.
-
DSO uses company gross accounts receivable from the Inquiry Reply: FY2023 CNY 159.70M; FY2024 CNY 225.24M; FY2025 CNY 295.03M.
Cash conversion cycle. Not meaningful. Accounts payable in standardised data include notes payable of CNY 472.9M at FY2025, which reflect bill financing rather than trade credit. That distorts days payable outstanding.
Commentary.
ROE: ROE settled at about 19% after the IPO equity raise. Asset turnover is only about 0.3× because of the CNY 1–1.7bn treasury book. Operating ROIC on productive assets is substantially higher than reported ROA implies.
Liquidity: The current ratio below 1.0 in FY2022–FY2023 and FY2025 is an artefact of bill-financing classification. Long-dated deposits sit in non-current assets while the matching bills sit in current liabilities. Guosen and Lanjing News nonetheless flag liquidity as "tight-balanced".
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (CNY Mn)
| Segment revenue (CNY Mn) | FY2024 | FY2025 |
|---|---|---|
Nucleating agents | 511.03 | 595.76 |
Synthetic hydrotalcite | 116.87 | 126.18 |
NDO compound additives | 57.72 | 59.86 |
Antioxidants | 70.63 | 113.97 |
Trading business | 115.61 | 81.41 |
Total main business | 871.86 | 977.18 |
Segment YoY growth (%) | FY2025 | — |
Nucleating agents | 16.58 | — |
Synthetic hydrotalcite | 7.97 | — |
NDO compound additives | 3.71 | — |
Antioxidants | 61.36 | — |
Trading business | -29.58 | — |
Segment share of revenue (%) | FY2024 | FY2025 |
Nucleating agents | 58.6 | 61.0 |
Synthetic hydrotalcite | 13.4 | 12.9 |
NDO compound additives | 6.6 | 6.1 |
Antioxidants | 8.1 | 11.7 |
Trading business | 13.3 | 8.3 |
Segment gross margin (%)
| Segment gross margin (%) | FY2024 | FY2025 |
|---|---|---|
Nucleating agents | 55.91 | 55.64 |
Synthetic hydrotalcite | 47.02 | 44.63 |
NDO compound additives | 24.92 | 23.62 |
Antioxidants | 14.93 | 11.60 |
Trading business | 7.14 | 30.23 |
Segment gross profit (CNY Mn, derived)
| Segment gross profit (CNY Mn, derived) | FY2024 | FY2025 |
|---|---|---|
Nucleating agents | 285.7 | 331.5 |
Synthetic hydrotalcite | 55.0 | 56.3 |
NDO compound additives | 14.4 | 14.1 |
Antioxidants | 10.5 | 13.2 |
Trading business | 8.3 | 24.6 |
Product revenue (CNY 100M)
| Product revenue (CNY 100M) | H1 2023 |
|---|---|
Nucleating agents | 2.04 |
Synthetic hydrotalcite | 0.48 |
Antioxidants | 0.38 |
Compound additives | 0.22 |
Trading goods | 0.56 |
Channel revenue (CNY Mn)
| Channel revenue (CNY Mn) | FY2024 | FY2025 |
|---|---|---|
End customers (self-produced) | 582.92 | 651.26 |
Traders (self-produced) | 173.34 | 244.51 |
Group Entities
| Entity | Role |
|---|---|
呈和科技股份有限公司 (parent) | Production (Baiyun), R&D, sales, trading |
广州科呈新材料有限公司 Guangzhou Kecheng New Materials | Nansha production base (IPO project) |
广州呈和塑料新材料有限公司 Guangzhou Chenghe Plastics New Materials | Trading and treasury; holder of time deposits |
上海呈和国际贸易有限公司 Shanghai Chenghe International Trade | Trading |
香港呈和科技有限公司 Hong Kong Chenghe Technology | Overseas sales hub; holds about CNY 550M of overseas cash and notes |
天津信达丰进出口贸易有限公司 Tianjin Xindafeng Import & Export | Trading (acquired 2023) |
广东呈和电子材料有限公司 Guangdong Chenghe Electronic Materials | Electronic-materials platform; Dongguan project owner |
广东聚讯新材料有限公司 Guangdong Juxun New Materials (80.89%) | Electronic PPO resin and HF/HS flame retardants |
PALMAROLE TRADING SAS (France, 100%) | European, Middle East and Americas distribution |
中电科翌智航(重庆)科技有限公司 (48%, associate) | Drone and low-altitude-economy systems |
Income statement (CNY Mn)
| Income statement (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 576.22 | 694.90 | 799.63 | 873.18 | 977.42 |
Gross profit | 254.74 | 291.06 | 348.08 | 375.01 | 439.91 |
SG&A | 51.71 | 62.15 | 80.12 | 90.13 | 96.13 |
R&D expense | 23.55 | 28.68 | 33.80 | 35.37 | 39.54 |
Operating income (EBIT, S&P basis) | 172.64 | 190.77 | 233.43 | 247.38 | 289.72 |
EBITDA | 181.96 | 200.77 | 250.32 | 266.87 | 322.14 |
Interest expense | 1.29 | 11.36 | 25.04 | 24.17 | 17.31 |
Interest and investment income | 5.95 | 32.37 | 52.40 | 70.11 | 60.98 |
Pre-tax income | 181.79 | 227.46 | 263.27 | 291.50 | 323.46 |
Income tax | 24.76 | 32.26 | 37.14 | 41.23 | 47.68 |
Net income attributable to parent | 157.03 | 195.20 | 226.13 | 250.27 | 275.79 |
Net income excluding non-recurring items | 147.40 | — | — | 234.96 | 263.75 |
Per-share data (CNY, bonus-adjusted)
| Per-share data (CNY, bonus-adjusted) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPS basic | 0.69 | 0.74 | 0.86 | 0.96 | 1.06 |
EPS diluted | 0.69 | 0.74 | 0.86 | 0.96 | 1.06 |
Dividend per share | 0.191 | 0 | 0.689 | 0.306 | 0.164 |
Margins (%)
| Margins (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 44.21 | 41.88 | 43.53 | 42.95 | 45.01 |
Operating margin (EBIT) | 29.96 | 27.45 | 29.19 | 28.33 | 29.64 |
EBITDA margin | 31.58 | 28.89 | 31.30 | 30.56 | 32.96 |
Pre-tax margin | 31.55 | 32.73 | 32.92 | 33.38 | 33.09 |
Net margin | 27.25 | 28.09 | 28.28 | 28.66 | 28.22 |
Effective tax rate | 13.62 | 14.19 | 14.11 | 14.14 | 14.74 |
Growth (%)
| Growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth | 25.19 | 20.60 | 15.07 | 9.20 | 11.94 |
Net income growth | 34.75 | 24.31 | 15.85 | 10.68 | 10.20 |
Income Statement and Margin Analysis (%)
| H1 comparison (CNY Mn) | H1 2025 | H1 2026 |
|---|---|---|
Revenue | 467.51 | 481.51 |
Total profit (pre-tax) | 170.43 | 143.53 |
Net income attributable | 147.25 | 128.73 |
Net income excluding non-recurring items | 136.59 | 105.94 |
Operating cash flow | 106.86 | 163.40 |
R&D (% of revenue) | 4.59 | 4.78 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansQuarterly revenue (CNY Mn)
| Quarterly revenue (CNY Mn) | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
Revenue | 266.47 | 237.44 | 249.18 | 232.33 |
Quarterly net income attributable (CNY Mn)
| Quarterly net income attributable (CNY Mn) | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
Net income | 80.54 | 48.00 | 90.19 | 38.54 |
Balance Sheet and Per-Share Data
| Balance sheet (CNY Mn, year-end) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 1,161 | 2,390 | 3,311 | 3,288 | 3,068 |
Cash and equivalents | 306.95 | 267.85 | 637.94 | 466.93 | 659.84 |
Cash and short-term investments | 538.02 | 383.42 | 1,137 | 1,690 | 971.32 |
Long-term investments (deposits, notes, fund, equities) | 160.62 | 1,365 | 1,395 | 604.63 | 960.99 |
Accounts receivable (S&P incl. notes) | 180.09 | 270.89 | 249.66 | 327.48 | 397.47 |
Inventory | 50.10 | 62.98 | 70.87 | 72.85 | 88.35 |
PP&E | 124.86 | 177.48 | 297.02 | 408.77 | 401.74 |
Goodwill | 0 | 0 | 19.36 | 19.36 | 19.36 |
Other intangibles | 42.66 | 41.29 | 46.83 | 45.05 | 43.30 |
Short-term debt | 1.34 | 868.11 | 1,509 | 1,393 | 854 |
Long-term debt (incl. lease liabilities) | 12.72 | 8.88 | 3.97 | 12.93 | 8.49 |
Total debt | 14.06 | 876.99 | 1,513 | 1,405 | 862.49 |
Net cash (positive) / net debt (negative), S&P | 523.96 | -493.57 | -375.46 | 284.46 | 108.82 |
Total liabilities | 251.81 | 1,333 | 2,034 | 1,928 | 1,563 |
Shareholders' equity | 908.80 | 1,057 | 1,277 | 1,361 | 1,505 |
Working capital | 548.34 | -562.07 | -477.67 | 313.24 | -14.15 |
Book value per share (CNY, adjusted) | 3.48 | 4.04 | 4.84 | 5.24 | 5.80 |
Cash flow (CNY Mn)
| Cash flow (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | 289.92 | 296.35 | 159.06 | 212.52 | 284.29 |
Capital expenditure | 69.33 | 75.63 | 114.94 | 110.66 | 66.37 |
Free cash flow | 220.59 | 220.72 | 44.12 | 101.86 | 217.92 |
Share buybacks | 0 | 0 | 23.82 | 76.18 | 0 |
FCF margin (%) | 38.28 | 31.76 | 5.52 | 11.67 | 22.30 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratios | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 25.82 | 19.86 | 19.38 | 18.98 | 19.25 |
ROA (%) | 13.75 | 6.72 | 5.12 | 4.69 | 5.70 |
ROIC (%) | 44.24 | 16.92 | 12.52 | 15.57 | 19.98 |
Current ratio (x) | 3.27 | 0.58 | 0.76 | 1.17 | 0.99 |
Quick ratio (x) | 2.99 | 0.50 | 0.69 | 1.07 | 0.90 |
Debt / equity (x) | 0.02 | 0.83 | 1.19 | 1.03 | 0.57 |
Net debt / EBITDA (x) | -2.88 | 2.46 | 1.50 | -1.07 | -0.34 |
Interest coverage, EBIT / interest (x) | 133.8 | 16.8 | 9.3 | 10.2 | 16.7 |
Asset turnover (x) | 0.73 | 0.39 | 0.28 | 0.27 | 0.31 |
Inventory turnover (x) | 7.58 | 7.14 | 6.75 | 6.93 | 6.67 |
Days inventory outstanding | 57 | 57 | 57 | 53 | 60 |
Days sales outstanding (gross AR basis) | — | — | 73 | 94 | 110 |
Region revenue (CNY Mn)
| Region revenue (CNY Mn) | FY2024 | FY2025 |
|---|---|---|
Domestic (PRC) | 699.81 | 714.62 |
Overseas | 172.05 | 262.56 |
Region growth (%) | FY2025 | — |
Domestic (PRC) | 2.1 | — |
Overseas | 52.61 | — |
Region share (%) | FY2024 | FY2025 |
Domestic (PRC) | 80.3 | 73.1 |
Overseas | 19.7 | 26.9 |
Region gross margin (%) | FY2024 | FY2025 |
Overseas | 49.61 | 56.94 |
Operating Areas
| Area | Trend | Drivers |
|---|---|---|
Overseas (all) | +52.6% in FY2025, with margin up 7.3 points | Nucleator cost advantage versus Milliken. China's 34% retaliatory tariff on US-origin goods (April 2025) raised costs for US nucleator imports into China and pushed buyers toward domestic suppliers, which helped domestic share. Overseas growth came from traders and international petrochemical qualification. The higher margin reflects the clarifier mix abroad. |
Domestic | +2.1% in FY2025 | Petrochemical demand was steady, but the trading business fell 29.6% (largely domestic). Self-produced domestic sales grew faster than the headline. |
Electronic materials (new) | From zero in FY2025 to consolidated Juxun revenue in FY2026 | Revenue not separately disclosed for H1 2026 |
Year-end share price (CNY, bonus-adjusted)
| Year-end share price (CNY, bonus-adjusted) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Close | 26.79 | 23.54 | 19.17 | 19.06 | 29.43 |
Market Valuation
| Market capitalisation (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Market cap | 7,484 | 6,523 | 5,308 | 5,058 | 7,642 |
Valuation Multiples (x)
| Valuation multiples (x) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
P/E | 47.66 | 33.42 | 23.47 | 20.21 | 27.71 |
EV/EBITDA | 38.53 | 32.74 | 25.15 | 21.06 | 23.45 |
EV/Sales | 12.17 | 9.46 | 7.87 | 6.44 | 7.73 |
P/B | 8.24 | 6.17 | 4.16 | 3.72 | 5.08 |
Valuation Snapshot
| Metric | Value |
|---|---|
Share price (CNY) | 66.58 |
Market cap (CNY Bn) | 17.29 |
Enterprise value (CNY Bn) | 17.14 |
P/E TTM (x) | 66.95 |
Forward P/E (x) | 50.66 |
P/B (x) | 10.48 |
EV/EBITDA TTM (x) | 56.73 |
EV/Sales TTM (x) | 17.29 |
P/FCF (x) | 60.39 |
Dividend yield (%) | 0.25 |
Beta | 1.51 |
52-week range, adjusted (CNY) | 22.06 – 99.94 |
Peer Valuation (X), Guosen 5 Jun 2026 Details
| Peer valuation (x), Guosen 5 Jun 2026 | GCH | Shengquan Group |
|---|---|---|
P/E FY2025 | 51.3 | 23.8 |
P/E FY2026E | 40.8 | 33.2 |
P/E FY2027E | 32.9 | 26.7 |
P/B FY2026E | 12.4 | 4.1 |
Income Statement
| Guosen forecasts (CNY Mn) | FY2024 | FY2025 | FY2026E | FY2027E | FY2028E |
|---|---|---|---|---|---|
Revenue | 882 | 977 | 1,222 | 1,503 | 1,803 |
Net income attributable | 250 | 276 | 347 | 430 | 522 |
Per-Share Data and Margin Analysis (%)
| Guosen forecasts (per share and %) | FY2024 | FY2025 | FY2026E | FY2027E | FY2028E |
|---|---|---|---|---|---|
EPS (CNY, diluted on latest share count) | 1.85 | 1.46 | 1.84 | 2.28 | 2.77 |
ROE (%) | 18.4 | 18.3 | 20.6 | 22.7 | 24.2 |
EBIT margin (%) | 27.8 | 30.0 | 31.4 | 31.4 | 31.4 |
Cash dividend declared (CNY Mn)
| Cash dividend declared (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|
Cash dividends | 50.00 | 0 | 180.56 | 42.66 |
Buybacks counted as dividends | 0 | 0 | 23.82 | 0 |
Payout ratio (%)
| Payout ratio (%) | FY2021 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|
Payout | 31.84 | 0 | 90.38 | 15.5 |
Maturity Profile At 31 Dec 2025 Details
| Maturity profile at 31 Dec 2025 (CNY Mn) | Value |
|---|---|
Short-term borrowings due within 12 months | 853.99 |
Of which: discounted bills not derecognised | 853.89 |
Long-term bank debt | 0 |
Lease liabilities, current | 5.04 |
Lease liabilities, non-current | 3.45 |
Analyst Conclusions
Management guidance
No quantitative revenue or profit guidance has been published. Qualitative priorities are:
-
ramping Nansha utilisation;
-
overseas expansion via Palmarole;
-
commercialising PPO and HF/HS flame retardants;
-
completing Dongguan phase one (technical renovation done June 2026; greenfield build ongoing);
-
launching the 4th-generation clarifier.
Consensus expectations
The only verified forecast set is Guosen's (June 2026): FY2026E net income CNY 347M (+25.7%), FY2027E CNY 430M (+24.1%) and FY2028E CNY 522M (+21.3%).
The H1 2026 actual was CNY 128.7M, which implies H2 2026 must deliver about CNY 218M to meet the FY2026E. That would be a 70% step-up on H1 and roughly 2.6× the H2 2025 level of about CNY 128.5M. The FY2026 forecast is at material risk of downward revision.
Bull case
-
Core franchise compounding plus operating leverage. Nucleator volumes grew 19% in FY2025 with flat 55% margins, and utilisation is only about 55%. Filling Nansha toward 80% would add earnings with minimal capex. Overseas sales grew 53% at a 57% margin, and Palmarole adds direct access to Borealis, BASF and Borouge.
-
Electronic-materials optionality. PPO and HF/HS flame retardants serve a supply-tight AI-server CCL chain where domestic suppliers are few (Guosen). Planned capacity of 2,500 t of each could become a second growth engine. Electronic PPO typically commands higher unit values than polymer additives (directional; not quantified in sources).
-
Balance-sheet and alignment support. Net cash is positive on the S&P definition (CNY 108.8M at FY2025), and the deposit book exceeds CNY 1bn. Insiders hold about 43% and bought CNY 60M of stock in August 2026. The new incentive plan ties 62 managers to performance.
Bear case
-
Earnings momentum has rolled over while the multiple has tripled. H1 2026 recurring net profit fell 22.4%; Q2 2026 net profit was the lowest quarter since listing at CNY 38.5M. Meanwhile trailing P/E expanded from about 28× (end-2025) to about 67×.
-
Capital-allocation and execution risk. The record of diversification is mixed: failed Yingri, loss-making Juxun, and drone and fund investments outside the core. Dongguan commits up to CNY 1.3bn, about 0.86× equity. Payout has been cut from 90% (FY2023) to 15.5% (FY2025).
-
Earnings-quality and disclosure flags. Receivables are growing 2.5× faster than revenue, and post-period collections are slowing. Bill-financing gross-up adds complexity, three periods were restated, and an SSE inquiry letter followed. The petrochemical customer base is under margin stress.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| Late Oct 2026 | Q3 2026 report | Whether Q3 net profit recovers above about CNY 70M; selling- and management-expense run-rate; FX |
| Q4 2026 | Electronic-materials disclosure | First segment revenue for PPO and flame retardants; named CCL customer qualifications (M6/M7 grades) |
| Q4 2026 – 2027 | Dongguan financing | Bank-loan versus equity issuance (dilution risk) |
| Ongoing | 4th-generation clarifier | Customer approvals versus Milliken Millad |
| Ongoing | Receivables and cash conversion | DSO trend (110 days at FY2025); collection of the CNY 41M FY2025 balance outstanding at 31 May 2026 |
| H1 2027 | FY2026 AR (about Apr 2027) | Dividend policy reset; utilisation; Palmarole contribution; goodwill testing (Juxun) |
| 2,027 | Incentive-plan vesting conditions | Performance hurdles |
| Macro | US–China trade measures; PP and PVC margins | Export-channel risk; customer payment behaviour |
Concluding analyst verdict
GCH Technology is a high-quality, small-cap specialty chemicals franchise that is now being priced as an electronic-materials growth platform before it has proven it can be one.
The core business is genuinely advantaged. Over five years the company has compounded revenue at 14% and net income at 15%, while holding net margins near 28% and earning about 19% ROE on an equity base inflated by cash. Its nucleating agents earn 55%+ gross margins against peers in the 25–31% range. It is the domestic champion in a market where imports still hold about two-thirds share. Overseas expansion at 57% margins and the Palmarole channel provide a credible runway that does not depend on any new technology.
The 2026 pivot changes the debate. The Juxun acquisition and the CNY 1.3bn Dongguan programme give real exposure to a supply-tight, AI-linked CCL materials chain. The market has capitalised that option generously: the shares are up about 2.3× year to date, at about 67× trailing earnings and over 10× book. Fundamental momentum, by contrast, has weakened:
-
H1 2026 recurring profit fell 22%;
-
Q2 2026 profit was a five-year low;
-
receivables are stretching;
-
capital is being redirected from dividends to an unproven segment, under an SSE inquiry spotlight.
On the evidence, the core business supports a premium specialty-chemicals valuation, and management's personal buying signals conviction. The current price, however, embeds successful electronic-materials execution that will not be visible in reported numbers until 2027 at the earliest. Guosen's FY2026 profit estimate appears too high given H1 delivery.
Our stance is constructive on franchise quality but cautious on valuation and near-term estimates. The decisive monitorables are disclosed PPO and flame-retardant revenue with named CCL qualifications, a Q3–Q4 2026 profit recovery, and receivables normalisation. Without them, the risk/reward skews to de-rating toward a core-business multiple, which historically sat at about 20–28× earnings.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Born / age | Tenure and background | Education | Shareholding |
|---|---|---|---|---|---|
Tong Jiaqi (仝佳奇) | Chairman; 4th-board nominee | Jul 1962 / 64 | Director since 2008; GM 2008–Jun 2024; chairman since Sep 2023. Previously at MOFTEC (Ministry of Foreign Trade, 1986–94), Sinochem (1994–97), Vice President at First Pacific Bank Hong Kong (1997–99), then Sinochem International (office head, plastics division GM, GM of Sinochem HK Chemical and Sinochem Plastics, 1999–2007). Executive director of Shanghai Kehui since 2007. | BA in World Economics; MBA | Indirect 12.01M shares (4.63%) via a 47% stake in Shanghai Kehui |
Zhao Wenlin (赵文林) | Founder, Honorary Chairman, director, chief engineer; controlling shareholder; 4th-board nominee | Oct 1964 / 61 | Founded the company in 2002; chairman 2002–Sep 2023. Previously technician at Guangzhou Huali Pigment Chemical (1988–92); deputy GM then GM at Guangzhou Yuanfeng Plastic Additives (1992–2002). | Chemical-engineering bachelor's; professor-level senior engineer | 100.03M shares (38.52%) direct plus via Zhongcheng |
Zhao Wensheng (赵文声) | Director since Sep 2021; nominee | Sep 1970 / 56 | Highway-engineering career: deputy GM at Guangdong Changda Highway Engineering; head of the Guangdong Highway Quality Monitoring Centre; head of Guangdong Road & Bridge Planning Research Centre; Beijing Xinqiao Technology. Brother of Zhao Wenlin. | PhD; senior economist | 19,600 shares |
Zhao Wenhao (赵文浩) | Director since Mar 2016; nominee | Feb 1973 / 53 | Engineering and equipment roles at the predecessor company (2004–16). Brother of Zhao Wenlin. | BA in Enterprise Management | 29,400 shares (indirect) |
Que Zhanwen (阙占文) | Independent director since Sep 2023; nominee | Feb 1979 / 47 | Law professor and PhD supervisor at Sun Yat-sen University; part-time lawyer; arbitrator | PhD | — |
Huang Guangming (黄光明) | Independent-director nominee (accounting expert) | Nov 1970 / 55 | Former CFO of Anjubao Digital and Gaolan Energy-Saving; current CFO of Guangzhou Chuangtian Electronic; independent director at Shenzhen Guanghua Weiye and Jiangsu Taimushi | BA in Accounting; senior accountant | — |
Liang Wenfei (梁文飞) | Independent-director nominee | May 1990 / 36 | Polymer and drug-delivery R&D roles (Baiyunshan Pharma; Dazhou Biomed; Kunshan Xinyunda) | BSc and MSc, Peking University | — |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Zhang Xu (张旭) | General Manager (CEO) | He succeeded Tong Jiaqi as GM after June 2024. Participated in the 2026 management share purchase. |
Yu Zhiliang (余志亮) | CFO | Previously head of the accounting function (Q1 2024 filings) |
Duan Shuli (段淑丽) | Investment Director | Participated in the 2026 share purchase |
Hu Zhiyi (胡志毅) | Board Secretary | Succeeded Yang Yanfang (Board Secretary in 2022) |
Chen Yinghong (陈映红) | Core employee; formerly head of accounting (2022–23) | Participated in the 2026 share purchase |
Board & Management Changes
| Date | Change |
|---|---|
Sep 2023 | Zhao Wenlin moves from chairman to Honorary Chairman; Tong Jiaqi becomes chairman (also GM) |
Jun 2024 | Tong Jiaqi relinquishes the GM role; Zhang Xu becomes GM |
Jul 2024 | Core technical staff member Wei Yongquan departs |
1 Jun 2026 | By-election of an independent director |
20 Aug 2026 | 4th-board slate nominated: incumbents re-nominated; two new independents (Huang, Liang) |
7 Sep 2026 | EGM to elect the 4th board. |
Major Shareholders
| Holder | Type | Stake (%) | Shares |
|---|---|---|---|
Zhao Wenlin | Individual (controlling shareholder) | 34.38 | 90,258,000 |
Ru Fei (茹菲) | Individual; acts in concert with Shanghai Kehui | 13.07 | 34,300,000 |
Shanghai Kehui Investment Management | Corporate (Tong Jiaqi holds 47%) | 9.74 | 25,561,476 |
Cui Hao (崔皓) | Individual | 3.83 | 10,058,277 |
Guangzhou Zhongcheng Investment LP | Employee/founder vehicle; acts in concert with Zhao | 3.73 | 9,800,000 |
Cai Jiayu | Individual | 1.22 | 3,214,400 |
Kuang Xiaoye | Individual | 1.07 | 2,806,361 |
He Jiayi | Individual | 0.77 | 2,027,990 |
Fullgoal Tianyi Value Hybrid Fund (Bank of Communications) | Mutual fund | 0.75 | 1,962,500 |
Wang Manli | Individual | 0.71 | 1,874,628 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Origin / listing | Positioning relative to GCH |
|---|---|---|---|
Nucleators and clarifiers | Milliken & Company (Millad, Hyperform) | US; private | Global technology and share leader in sorbitol clarifiers. GCH positions its products as comparable in performance and cheaper (Guosen, Apr 2025). |
Nucleators | ADEKA Corporation (ADK STAB NA series) | Japan; TSE 4401 | Phosphate-ester nucleator leader. Also a GCH customer for hydrotalcite and antioxidants (co-opetition). |
Nucleators | New Japan Chemical (Rikaclear / Gel All) | Japan; TSE 4406 | Sorbitol clarifier competitor |
Nucleators / additives | BASF (Irgaclear, Irganox) | Germany; XETRA BAS | Broad additive portfolio; global scale |
Synthetic hydrotalcite | Kyowa Chemical Industry | Japan; private | High-end hydrotalcite leader (imports into China) |
Synthetic hydrotalcite | Sakai Chemical Industry | Japan; TSE 4078 | High-end PVC and PP hydrotalcite |
Synthetic hydrotalcite / additives | Clariant | Switzerland; SIX CLN | Named by Guosen as a high-end hydrotalcite incumbent |
Antioxidants | Songwon Industrial | Korea; KRX 004430 | Global #2 polymer stabiliser maker |
Antioxidants / light stabilisers | Rianlon (利安隆) | China; SZSE 300596 | Domestic stabiliser leader with far larger antioxidant scale |
Electronic PPO resin | SABIC; Mitsubishi Gas Chemical; Asahi Kasei | Saudi Arabia; Japan (TSE 4182, TSE 3407) | Global PPO capacity is concentrated here (Guosen) |
Electronic PPO resin | Shengquan Group (圣泉集团) | China; SSE 605589 | Domestic leader in electronic resins; market cap about CNY 44.6bn (Jun 2026) |
Electronic PPO resin | Dongcai Technology (东材科技) | China; SSE 601208 | Domestic electronic-resin producer |
HF/HS flame retardants | Jinyi Chemical (晋一化工) | Taiwan | Current main supplier for M6-and-above CCL flame retardants (Guosen) |
Polymer additives (company-chosen comparables) | Tongcheng New Materials (彤程新材); Yoke Technology (雅克科技); Huicheng Environmental (惠城环保) | China A-shares | Used by GCH in its own margin benchmarking |
Competitor Detail
| Gross margin (%) | FY2024 | FY2025 |
|---|---|---|
GCH Technology | 43.53 | 45.02 |
Tongcheng New Materials | 24.84 | 24.20 |
Yoke Technology | 31.59 | 30.96 |
Huicheng Environmental | 24.74 | 29.17 |
Peer average | 27.06 | 28.11 |
Competitor Detail — GCH Technology
| Inventory write-down ratio, end-2025 (%) | Value |
|---|---|
GCH Technology | 0.11 |
Tongcheng New Materials | 1.73 |
Yoke Technology | 2.65 |
Huicheng Environmental | 0.02 |
Valuation versus closest electronic-resin peer (Guosen, 5 Jun 2026) | GCH |
Market cap (CNY 100M) | 197 |
EPS FY2025 (CNY) | 1.46 |
EPS FY2026E (CNY) | 1.84 |
P/E FY2026E (x) | 40.8 |
P/B FY2026E (x) | 12.4 |
Recent Developments
--



